MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
series a convertible...
$4,940K
Proceeds from issuance of
common...
$4,916K
Proceeds from 2025
convertible note, net
$4,913K
Proceeds from issuance of
common stock-At The...
$2,628K
Proceeds from the
exercise of stock options
$15K
Net cash provided by
financing activities
$17,412K
Net decrease in cash
and cash...
-$616K
Canceled cashflow
$17,412K
Stock-based compensation
$3,793K
Accounts payable
$1,197K
Prepaid expenses and
other assets
-$673K
Common stock issued to
consultant for services...
$226K
Non-cash lease expense
$203K
Loss on sale of
subsidiary
-$166K
Non-cash interest
expense
$138K
Loss on disposal of
property and equipment
-$91K
Depreciation and
amortization
$73K
Amortization of debt issuance
costs and debt...
$58K
Restricted stock units
released to consultant...
$29K
Other current
liabilities
$18K
Net cash used in
operating activities
-$17,955K
Canceled cashflow
$6,665K
Net cash used in
investing activities
-$59K
Effect of foreign
currency on cash and cash...
-$14K
Net loss
-$19,215K
Change in fair value of
warrants liabilities
-$4,263K
Gain on warrants
expiration
$724K
Accrued expenses
-$231K
Operating lease
liabilities
-$187K
Purchase of equipment
$59K
Back
Back
Cash Flow
source: myfinsight.com
Serina Therapeutics, Inc. (SER)
Serina Therapeutics, Inc. (SER)